Results 21 to 30 of about 32,676 (224)

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

Frontiers in Pharmacology, 2022
The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr, Andrea Zimmermann, Friedeborg Seitz, Angelika Dienel   +3 more
doaj   +1 more source

Rivaroxaban versus warfarin for the management of left ventricle thrombus

The Egyptian Heart Journal, 2021
Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with ...
Monirah A. Albabtain, Yahya Alhebaishi, Ola Al-Yafi, Hatim Kheirallah, Adel Othman, Haneen Alghosoon, Amr A. Arafat, Ahmed Alfagih   +7 more
doaj   +1 more source

Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Patients with single‐ventricle physiology who undergo the Fontan procedure are at risk for thrombotic events associated with significant morbidity and mortality.
Brian W. McCrindle, Alan D. Michelson, Andrew H. Van Bergen, Estela Suzana Horowitz, Juan Pablo Sandoval, Henri Justino, Kevin C. Harris, John L. Jefferies, Liza Miriam Pina, Colleen Peluso, Kimberly Nessel, Wentao Lu, Jennifer S. Li   +12 more
doaj   +1 more source

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice [PDF]

, 2018
Kavitha Vimalesvaran,1 Seth J Dockrill,1 Diana A Gorog1–3 1Department of Cardiology, East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, UK; 2School of Life and Medical Sciences, Postgraduate Medical School, University of ...
Gorog DA, Diana A Gorog, Seth Dockrill, Kavitha Vimalesvaran, Vimalesvaran K, Gorog, Diana, Vimalesvaran, Kavitha, Dockrill SJ, Dockrill, Seth J   +8 more
core   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Rivaroxaban [PDF]

pharma-kritik, 2009
Ein direkter Hemmer von Faktor-Xa, der oral verabreicht werden kann. Dieses Antikoagulans ist bisher zur Thromboembolie-Prophylaxe nach grossen orthopädischen Eingriffen zugelassen. Sein Nutzen/Risiko-Profil ist noch ungenügend definiert.
openaire   +1 more source

Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice

Scientific Reports, 2017
Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang, Junjie Shao, Ruifeng Hu, Haimei Chen, Ping Xie, Chang Liu   +5 more
doaj   +1 more source

Rivaroxaban in atrial fibrillation cardioversion: an update [PDF]

, 2019
Carlo Lavalle, Martina Straito, Annalisa Caroli, Agostino Piro, Giuseppe Giunta, Marco Valerio Mariani, Francesco FedeleDepartment of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, “Sapienza” University ...
Giunta G, Straito M, Lavalle C, Mariani MV, Lavalle C., Giunta G., Piro A., Fedele F, Mariani M. V., Piro A, Caroli A., Fedele F., Caroli A, Straito M.   +13 more
core   +1 more source

Update on Rivaroxaban

, 2010
Anticoagulants are recommended for the prevention and treatment of venous thromboembolism (VTE). The new anticoagulants which target specific factors in the coagulation cascade offer the advantage that they can be administered orally. These drugs seek to
Dipankar Chattopadhyay, Osama Moussa, Vish Bhattacharya   +2 more
core   +1 more source

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement [PDF]

, 2020
BACKGROUND Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.
Makkar, Raj R, Giustino, Gennaro, Zazula, Ana, Søndergaard, Lars, Wildgoose, Peter, Tchétché, Didier, Möllmann, Helge, Welsh, Robert C., Kini, Annapoorna, Curzen, Nicholas, Mack, Michael, Welsh, Robert C, Thomitzek, Karen, Volkl, Albert A, De Backer, Ole, GALILEO, Moellmann, Helge, Dangas, George D., Schäfer, Ulrich, Guimaraes, Ana H. C., van Amsterdam, Ronald G M, Tijssen, Jan G.P., Sondergaard, Lars, van Amsterdam, Ronald G. M., Schaefer, Ulrich, Moreno, Raúl, Gullestad, Lars, Guimarães, Ana H C, Vranckx, Pascal, Guimarães, Ana H.C., GALILEO Investigators, Dangas, George D, Kreuzpointner, Robert, van Amsterdam, Ronald G.M., Tijssen, Jan G P, Woehrle, Jochen, Windecker, Stephan, Volkl, Albert A., Herrmann, Howard C., Baldus, Stephan, von Lewinski, Dirk, Seeger, Julia, Makkar, Raj R., Gilard, Martine, Tijssen, Jan G. P., Wöhrle, Jochen, Herrmann, Howard C, Valgimigli, Marco, Mehran, Roxana   +48 more
core   +1 more source